Clinical Efficacy of Atorvastatin Calcium Tablets Combined with Budesonide and Formoterol Fumarate Powder for Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease and its Influence on Blood Gas Analysis Parameters
Objective:To explore the clinical efficacy of atorvastatin calcium tablets combined with budesonide and formoterol fumarate powder for inhalation in patients with chronic obstructive pulmonary disease(COPD)and its effects on blood gas analysis parameters.Methods:A total of 120 COPD patients admitted to a hospital from December 2021 to December 2023 were selected as subjects and divided into the control group and the observation group using random number table method,with 60 cases in each group.The control group were treated with budesonide and formoterol fumarate powder for inhalation(Ⅱ),and the observation group were treated with atorvastatin calcium tablets in addition to the treatment of the control group,and both groups were treated continuously for 4 weeks.The clinical efficacy,pulmonary function[forced vital capacity(FVC),peak expiratory flow(PEF)and forced expiratory volume in one second to forced vital capacity(FEV1/FVC)],blood gas analysis parameters[arterial partial pressure of oxygen(PaO2),arterial partial pressure of carbon dioxide(PaCO2)and blood oxygen saturation(SO2)],the ratio of helper T cell 1/helper T cell 2(Th1/Th2)and the ratio of helper T cell 17/regulatory T cell(Th17/Treg),and the occurrence of adverse reactions were compared between the two groups.Results:Following treatment,the overall response rate of the observation group(93.33%)was higher than that of the control group(75.00%,P<0.05).FVC,PEF,and FEV1/FVC increased in both groups(P<0.05),with higher results in the observation group(P<0.05);PaO2 and SO2 increased in both groups(P<0.05),with higher results in the observation group(P<0.05);PaCO2 decreased in both groups(P<0.05),with lower results in the observation group(P<0.05);Th1/Th2 and Th17/Treg ratios decreased in both groups(P<0.05),with lower ratios in the observation group(P<0.05).The overall incidence of adverse reactions showed no statistically significant difference between the two groups(P>0.05).Conclusion:Better clinical efficacy can be expected with combination treatment of atorvastatin calcium tablets and budesonide and formoterol fumarate powder for inhalation in the treatment of COPD than single budesonide and formoterol fumarate powder for inhalation,which can effectively improve lung function and blood gas analysis parameters in patients with COPD,and does not increase the risk of adverse reactions.
atorvastatin calcium tabletsbudesonide and formoterol fumarate powder for inhalationchronic obstructive pulmonary diseaseblood gas analysis parameterslung function
国家科技期刊平台
NSTL
万方数据
